Editas Medicine Inc. (EDIT) Director Sells $337,450.80 in Stock
Editas Medicine Inc. (NASDAQ:EDIT) Director Kevin Bitterman sold 21,480 shares of Editas Medicine stock in a transaction on Wednesday, November 23rd. The stock was sold at an average price of $15.71, for a total value of $337,450.80. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Kevin Bitterman also recently made the following trade(s):
- On Tuesday, November 15th, Kevin Bitterman sold 88,900 shares of Editas Medicine stock. The stock was sold at an average price of $16.96, for a total value of $1,507,744.00.
Editas Medicine Inc. (NASDAQ:EDIT) opened at 14.27 on Thursday. The company has a 50-day moving average price of $14.53 and a 200-day moving average price of $21.47. Editas Medicine Inc. has a 1-year low of $12.43 and a 1-year high of $43.99. The firm’s market cap is $508.50 million.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.05. Editas Medicine had a negative return on equity of 59.22% and a negative net margin of 1,184.46%. The business earned $1 million during the quarter, compared to the consensus estimate of $1 million. The business’s revenue for the quarter was up 49.3% compared to the same quarter last year. On average, equities research analysts forecast that Editas Medicine Inc. will post ($2.49) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this news story can be read at http://www.dailypolitical.com/2016/12/01/editas-medicine-inc-edit-director-sells-337450-80-in-stock.html.
A number of research firms have recently weighed in on EDIT. Zacks Investment Research raised Editas Medicine from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a report on Thursday, November 10th. Jefferies Group reaffirmed a “buy” rating on shares of Editas Medicine in a research note on Monday, August 22nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $30.75.
A number of large investors have recently made changes to their positions in EDIT. FMR LLC increased its position in shares of Editas Medicine by 0.9% in the second quarter. FMR LLC now owns 5,452,061 shares of the company’s stock worth $133,030,000 after buying an additional 50,031 shares during the period. Flagship Ventures Fund IV General Partner LLC acquired a new position in shares of Editas Medicine during the second quarter worth about $120,910,000. Price T Rowe Associates Inc. MD increased its position in shares of Editas Medicine by 32.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,874,396 shares of the company’s stock worth $25,267,000 after buying an additional 460,280 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Editas Medicine by 159.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 170,739 shares of the company’s stock worth $2,302,000 after buying an additional 104,808 shares during the period. Finally, BlackRock Fund Advisors increased its position in shares of Editas Medicine by 2.8% in the second quarter. BlackRock Fund Advisors now owns 163,385 shares of the company’s stock worth $3,987,000 after buying an additional 4,466 shares during the period. Institutional investors and hedge funds own 60.89% of the company’s stock.
Editas Medicine Company Profile
Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.
Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.